Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Keywords
neurotoxicity, radiation toxicity, cognitive/functional effects, tumors metastatic to brain, unspecified adult solid tumor, protocol specific
Brief summary
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether stereotactic radiosurgery is more effective than whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery. PURPOSE: This randomized phase III trial studies how well stereotactic radiosurgery works compared to whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery.
Detailed description
Primary Goals 1. Overall Survival - To determine in patients with one to four brain metastases whether there is improved overall survival in patients who receive SRS to the surgical bed compared to patients who receive WBRT. 2. Neurocognitive Progression - To determine in patients with one to four brain metastases whether there is less neurocognitive progression post-randomization in patients who receive SRS to the surgical bed compared to patients who receive WBRT. Secondary Goals 1. Quality of Life (QOL) - To determine in patients with resected brain metastases whether there is improved QOL in patients who receive SRS to the surgical bed compared to patients who receive WBRT. 2. Central Nervous System Failure - To determine in patients with one to four brain metastases whether there is equal or longer time to central nervous system (CNS) failure (brain) in patients who receive SRS to the surgical bed compared to patients who receive WBRT. 3. Functional Independence - To determine in patients with one to four brain metastases whether there is longer duration of functional independence in patients who receive SRS to the surgical bed compared to patients who receive WBRT. 4. Long-Term Neurocognitive Status - To determine in patients with one to four brain metastases whether there is better long-term neurocognitive status in patients who receive SRS to the surgical bed compared to patients who receive WBRT. 5. Adverse Events - To tabulate and descriptively compare the post-treatment adverse events associated with the interventions. 6. Local Tumor Bed Recurrence - To evaluate local tumor bed recurrence at 6 months with post-surgical SRS to the surgical bed in comparison to WBRT. 7. Local Recurrence - To evaluate time to local recurrence with post-surgical SRS to the surgical bed in comparison to WBRT. 8. CNS Failure Patterns - To evaluate if there is any difference in CNS failure patterns (local, distant, leptomeningeal) in patients who receive SRS to the surgical bed compared to patients who receive WBRT. OUTLINE: This is a multicenter study. Patients are stratified according to age in years (\< 60 vs ≥ 60), extracranial disease controlled (≤ 3 months vs \> 3 months), number of pre-operative brain metastases (1 vs 2-4), histology (lung vs radioresistant \[brain metastases from a sarcoma, melanoma, or renal cell carcinoma histology\] vs other), and resection cavity maximal diameter (≤ 3 cm vs \> 3 cm). Patient must complete baseline QOL and neurocognitive tests prior to registration/randomization. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo whole-brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. * Arm II: Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Event monitoring occurs up to 5 years post registration/randomization.
Interventions
RADIATIONstereotactic radiosurgery
Undergo RT
RADIATIONwhole-brain radiation therapy
Undergo radiotherapy (RT)
Sponsors
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Pre-registration Inclusion Criteria: 1. Number of Brain Metastases - Four or fewer brain metastases (as defined on the pre-operative MRI or CT brain scan) and status post resection of one of the lesions. 2. Non-CNS Primary Site - Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site. Note: Patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site. 3. Size of Metastases - Any unresected lesions must measure \< 3.0 cm in maximal extent on the contrasted MRI or CT brain scan obtained ≤ 35 days prior to pre-registration. The unresected lesions will be treated with SRS as outlined in the treatment section of the protocol. Note: The metastases size restriction does not apply to the resected brain metastasis; with resected brain metastases only surgical cavity size determines eligibility. 4. Size of Resection Cavity - Resection cavity must measure \<5.0 cm in maximal extent on the post-operative MRI or CT brain scan obtained ≤35 days prior to pre-registration. Note: It is permissible for the resection of a dominant brain metastasis to include a smaller satellite metastasis as long as the single resection cavity is less than the maximum size requirements. 5. Tumor Staging Procedures - All standard tumor-staging procedures necessary to define baseline extra cranial disease status completed ≤42 days prior to pre-registration. 6. Treatment with Gamma Knife or Radiosurgery - Able to be treated with either a gamma knife or a linear accelerator-based radiosurgery system. 7. Age ≥ 18 years 8. Neurocognitive Testing - Willing and able to complete neurocognitive testing without assistance from family and companions. Note: Because neurocognitive testing is one of the primary goals of this study, patients must be able to utilize English language booklets (and/or French booklets if enrolled in Canada). 9. Quality of Life (QOL) Questionnaires - Willing and able to complete QOL by themselves or with assistance 10. ECOG Performance Status - ECOG Performance Status (PS) 0, 1, or 2. 11. SRS Credentialed by IROC Houston Quality Assurance - The site's SRS facility is IROC Houston Quality Assurance approved. 12. Neurocognitive Testing Credentialing - The site study team member performing neurocognitive testing of patients must have credentialing confirming completion of the neurocognitive testing training of the protocol. 13. Written Informed Consent - Provide written informed consent 14. Mandatory Samples for Correlative Tests - Willing to provide mandatory blood and urine samples for correlative research purposes. Pre-registration
Exclusion criteria
1. Pregnancy, Nursing and Contraception - pregnant women, nursing women and men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment. 2. Prior Cranial Radiation Therapy 3. MRI or CT Scans - Inability to complete a MRI or CT scan with contrast of the head. 4. Gadolinium Allergy - Known allergy to gadolinium. 5. Cytotoxic Chemotherapy - Planned cytotoxic chemotherapy during the SRS or WBRT. 6. Other Tumor Types - Primary germ cell tumor, small cell carcinoma, or lymphoma 7. Leptomeningeal Metastasis - Widespread definitive leptomeningeal metastasis 8. Location of Brain Metastasis - A brain metastasis that is located ≤ 5 mm of the optic chiasm or within the brainstem. Randomization Inclusion Criteria: 1. Number of Unresected Lesions - Post-operative MRI or CT scan confirmed zero, one, two or three unresected lesions. 1.1 Each unresected lesion must measure ≤ 3.0 cm in maximal extent on the contrasted post-operative MRI or CT brain scan. 1.2 Note: The pre-registration, post-operative, brain scan may be used for the randomization scan if obtained ≤ 28 days prior to randomization. 1.3 Note: If there are no unresected brain metastases (i.e., all brain metastases have been resected), a post-operative CT brain scan may be used if obtained ≤ 28 days prior to randomization. 2. Size of Resection Cavity - Post-operative MRI or CT scan confirms resection cavity measures \< 5.0 cm in maximal extent. 2.1 Note: The pre-registration, post-operative brain scan may be used for the randomization scan if obtained ≤ 28 days prior to randomization. 2.2 Note: If there are no unresected brain metastases (i.e., all brain metastases have been resected), a post-operative CT brain scan may be used if obtained ≤28 days prior to randomization. 3. Urine or Serum Pregnancy Test - Negative urine or serum pregnancy test done ≤ 7 days prior to randomization, for women of child bearing potential only. Randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT | from baseline up to 5 years post radiation | To determine in patients with one to four brain metastases whether there is less nuerocognitive progression post-randomization in patients who receive SRS to the surgical bed compared to patients who receive WBRT. Neurocognitive progression is defined as a drop of at least one stanard deviation from baseline in one of the six neurocognitive tests at post-randomization evaluation. |
| Overall Survival | from baseline up to 5 years post radiation | To determine in patients with one to four brain metastases whether there is improved overall survival in patients who receive SRS to the surgical bed compared to patients who receive WBRT. Overall survival is defined as the time from randomization to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Control of the Surgical Bed | Up to 6 months post radiation | Local control of the surgical bed means that tumor did not recur at the unresected metastases treated with stereotactic radiosurgery, SRS, or whole brain radiotherapy, WBRT. Intercranial Brain Control Rates estimated via 1-Cumulatice Incidence Rate from Competing Risk survival analysis of time to the specific recurrence type. Deaths without recurrence are censored at time of death. |
| Time to CNS Failure in These Patients | Up to 5 years post radiation | — |
| Change in Quality-of-life at 6 Months | Up to 6 months post randomization | Clinically significant change in quality of life is defined as ten-point change on QOL scores (transformed to a 0 to 100 scale). As measured by the overall score from the FACT-Br. An improvement is defined as a change greater than or equal ten points. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I - WBRT Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
whole-brain radiation therapy: Undergo radiotherapy (RT) | 96 |
| Arm II - SRS Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
stereotactic radiosurgery: Undergo RT | 98 |
| Total | 194 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal prior to treatment | 4 | 5 |
Baseline characteristics
| Characteristic | Arm I - WBRT | Arm II - SRS | Total |
|---|---|---|---|
| Age, Continuous | 62 years | 61 years | 61 years |
| Region of Enrollment North America | 96 participants | 98 participants | 194 participants |
| Sex: Female, Male Female | 46 Participants | 52 Participants | 98 Participants |
| Sex: Female, Male Male | 50 Participants | 46 Participants | 96 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 74 / 92 | 64 / 93 |
| serious Total, serious adverse events | 14 / 92 | 19 / 93 |
Outcome results
Primary
Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT
To determine in patients with one to four brain metastases whether there is less nuerocognitive progression post-randomization in patients who receive SRS to the surgical bed compared to patients who receive WBRT. Neurocognitive progression is defined as a drop of at least one stanard deviation from baseline in one of the six neurocognitive tests at post-randomization evaluation.
Time frame: from baseline up to 5 years post radiation
Population: All enrolled patients were included in the analysis of this outcome. This includes the 9 patients that did not receive treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I - WBRT | Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT | 3.0 Months |
| Arm II - SRS | Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT | 3.7 Months |
p-value: <0.000195% CI: [0.35, 0.63]Log Rank
Primary
Overall Survival
To determine in patients with one to four brain metastases whether there is improved overall survival in patients who receive SRS to the surgical bed compared to patients who receive WBRT. Overall survival is defined as the time from randomization to death from any cause.
Time frame: from baseline up to 5 years post radiation
Population: All enrolled patients were included in the analysis of this outcome. This includes the 9 patients that did not receive treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I - WBRT | Overall Survival | 11.6 months |
| Arm II - SRS | Overall Survival | 12.2 months |
p-value: 0.795% CI: [0.76, 1.5]Log Rank
Secondary
Change in Quality-of-life at 6 Months
Clinically significant change in quality of life is defined as ten-point change on QOL scores (transformed to a 0 to 100 scale). As measured by the overall score from the FACT-Br. An improvement is defined as a change greater than or equal ten points.
Time frame: Up to 6 months post randomization
Population: Only patients with baseline and 6 month QOL assessment scores were included in this analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I - WBRT | Change in Quality-of-life at 6 Months | Improvement | 4 participants |
| Arm I - WBRT | Change in Quality-of-life at 6 Months | Stable | 24 participants |
| Arm I - WBRT | Change in Quality-of-life at 6 Months | Decline | 17 participants |
| Arm I - WBRT | Change in Quality-of-life at 6 Months | Missing | 19 participants |
| Arm II - SRS | Change in Quality-of-life at 6 Months | Missing | 14 participants |
| Arm II - SRS | Change in Quality-of-life at 6 Months | Improvement | 6 participants |
| Arm II - SRS | Change in Quality-of-life at 6 Months | Decline | 12 participants |
| Arm II - SRS | Change in Quality-of-life at 6 Months | Stable | 33 participants |
p-value: 0.31Chi-squared
Secondary
Local Control of the Surgical Bed
Local control of the surgical bed means that tumor did not recur at the unresected metastases treated with stereotactic radiosurgery, SRS, or whole brain radiotherapy, WBRT. Intercranial Brain Control Rates estimated via 1-Cumulatice Incidence Rate from Competing Risk survival analysis of time to the specific recurrence type. Deaths without recurrence are censored at time of death.
Time frame: Up to 6 months post radiation
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I - WBRT | Local Control of the Surgical Bed | 87.1 percentage of patients |
| Arm II - SRS | Local Control of the Surgical Bed | 80.4 percentage of patients |
p-value: 0.00068Gray's K-sample
Secondary
Time to CNS Failure in These Patients
Time frame: Up to 5 years post radiation
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I - WBRT | Time to CNS Failure in These Patients | 27.5 Months |
| Arm II - SRS | Time to CNS Failure in These Patients | 6.4 Months |